Resistin's role in inflammation related to pulmonary hypertension
Resistin regulates NLRP3 inflammasome in pulmonary hypertension
This study is looking at how a protein called resistin affects inflammation in people with pulmonary hypertension, with the hope of finding new ways to improve treatments for this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10903720 on NIH RePORTER |
What this research studies
This research investigates how a protein called resistin influences inflammation in pulmonary hypertension (PH), a serious condition affecting blood vessels in the lungs. The study aims to understand the mechanisms by which resistin contributes to the activation of the NLRP3 inflammasome, a key player in the inflammatory response. By using rodent models and analyzing patient samples, the researchers will explore how resistin levels correlate with disease severity and outcomes. The goal is to uncover new insights that could lead to better treatments for patients suffering from PH.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary hypertension, particularly those with idiopathic pulmonary arterial hypertension or scleroderma-related pulmonary hypertension.
Not a fit: Patients with pulmonary hypertension caused by other factors, such as left heart disease or chronic lung disease, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that target inflammation in pulmonary hypertension, potentially improving patient outcomes.
How similar studies have performed: Previous research has shown that targeting inflammatory pathways in pulmonary hypertension can lead to significant improvements, suggesting that this approach may also be promising.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Johns, Roger a — Johns Hopkins University
- Study coordinator: Johns, Roger a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.